Market Overview

CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

Share:

NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced that management will participate in four investor conferences in March, including the 31st Annual ROTH Conference in Laguna Niguel, California, the Oppenheimer 29th Annual Healthcare Conference in New York City, the Oppenheimer's Biotech Summit by the Lake at Northwestern University in Evanston, Illinois, and the ROTH Battle of NASH Thrones Spring Investor Conference in New York City.

31st Annual ROTH Conference
Date: Monday, March 18
Time: 9:30am Pacific Time
Format: Panelist: Why Knowing NASH as a Generalist Can Make You Rich in 2019
   
Time: 12:00pm Pacific Time
Format: Fireside Chat
Webcast: http://ir.cymabay.com/events
   
Oppenheimer 29th Annual Healthcare Conference
Date: Tuesday, March 19
Time: 8:35am Eastern Time
Format: Fireside Chat
Webcast: http://ir.cymabay.com/events
   
Oppenheimer's Biotech Summit by the Lake
Date: Wednesday, March 27
Time: 1:00pm Central Time
Format: Corporate Presentation
   
ROTH Battle of NASH Thrones Spring Investor Conference
Date: Thursday, March 28
Time: 8:00 am Eastern Time
Format: Panel:  12 Months of Data - 2019 Is the Year for FXR and PPAR Clinical Readouts
   
Time: 4:00pm Eastern Time
Format: Panel: Why MRI May Hold the Key to the Kingdom in Diagnosis and Drug Development

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead development candidate, seladelpar, is a potent, selective and orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation for PBC from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation for PBC from the FDA and Priority Medicine status from the EMA. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

CBAY Logo.jpg

View Comments and Join the Discussion!
 
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com